Medicare to cover Merck drug to treat nausea
Key points
- Inc.'s drug, Emend, when used with two other drugs to treat nausea and Vomiting in cancer patients receiving certain chemotherapy, U.S. officials said on Tuesday.
- Emend, also known as aprepitant, will be covered when added to treatments given before patients receive highly emetogenic chemotherapy, which can cause severe symptoms, said Medicare, the national health program for the elderly and disabled.
Medicare will pay for Merck & Co. Inc.'s drug, Emend, when used with two other drugs to treat nausea and Vomiting in cancer patients receiving certain chemotherapy, U.S. officials said on Tuesday.
Emend, also known as aprepitant, will be covered when added to treatments given before patients receive highly emetogenic chemotherapy, which can cause severe symptoms, said Medicare, the national health program for the elderly and disabled.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsHIV drug shows efficacy in treating mouse models of HER2+ breast cancer
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of…
9 October 2012
NewsDrugs for ovarian tumor can treat breast cancer
The most comprehensive analysis yet of breast cancer has revealed that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers. The findings suggest that most…
25 September 2012
NewsTreatment of breast cancer could change with discovery
Scientists announced Sunday that they have finished mapping virtually all of the genetic mutations in breast cancer, an effort that could soon change the way patients are treated and help researchers develop better…
24 September 2012
